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DNAbinding is central to the ability of p53 to function as a tumor
suppressor. In linewith the remarkable functional versatility of p53,
which can act on DNA as a transcription, repair, recombination,
replication, and chromatin accessibility factor, the modes of p53
interaction with DNA are also versatile. One feature common to all
modes of p53-DNA interaction is the extraordinary sensitivity of
p53 to the topology of its target DNA.Whereas the strong impact of
DNA topology has been demonstrated for p53 binding to sequence-
specific sites or to DNA lesions, the possibility that DNA structure-
dependent recognition may underlie p53 interaction with other
types of DNA has not been addressed until now. We demonstrate
for the first time that conformationally flexible CTGCAG trinucle-
otide repeats comprise a novel class of p53-binding sites targeted by
p53 in a DNA structure-dependent mode in vitro and in vivo. Our
major finding is that p53 binds to CTGCAG tracts by different
modesdependingon the conformationofDNA.Althoughp53binds
preferentially to hairpins formed by either CTG or CAG strands, it
can also bind to linear forms of CTGCAG tracts such as canonic B
DNA or mismatched duplex. Intriguingly, by binding to a mis-
matched duplex p53 can induce further topological alterations in
DNA, indicating that p53 may act as a DNA topology-modulating
factor.
Cells are equipped with extraordinarily sensitive surveillance sys-
tems, which are able to monitor genomic DNA for the appearance of
any unprogrammed alterations that may pose a danger to the structural
integrity of the genome (1–4). The appearance of just one or two double
strand breaks in a cell is sufficient for rapidly putting the system into a
“high alert” mode, marked by the activation of signaling pathways that
are responsive to DNA damage (5–7). The ability to function either in a
“stand by” or in an activated high alert mode is also a hallmark of the
tumor suppressor p53, one of the key factors involved in the mainte-
nance of genomic integrity (8–11). Activation of p53 is an essential
component of the global response of the cell to acute genotoxic insults
that leads to rapid stabilization of the p53 protein and to p53 functioning
in a high alert mode (12, 13). As a DNA damage-inducible factor, p53
can be potently activated by various types of genotoxic stimuli (9, 14,
15). A causative relationship between the occurrence of damaged DNA
and the activation of the p53 response has been established by studies in
a cell-free system demonstrating that sequence-specific DNA binding
of p53 (p53-SSDB) can be potently stimulated by free DNA ends (16). In
vitroDNA binding analyses further revealed that the C-terminal DNA-
binding domain of p53 can bind selectively to some types of aberrant
DNA structures in a sequence-independent manner (17–19). These
findings led to the proposal that p53may recruit cellular repair factors to
the sites of damage by directly binding to DNA lesions in a DNA
structure-dependent fashion (20, 21). Notably, it appears that such
sequence-independent and DNA structure-selective DNA binding of
p53 (p53-DSSB) may not necessarily be exclusively associated with
damaged DNA, because some types of DNA structures to which p53
binds with high affinity in vitro can form in cells under physiological
conditions. Indeed, non-canonic DNA structures such as cruciforms,
hemicatenated DNA, DNA bulges, three- and four-way junctions, or
telomeric t-loops can all be bound by p53 (18, 19, 22–25).
Previous studies provided valuablemechanistic insights into the prin-
cipal features that appear to be characteristic of p53-DSSB. p53-DSSB is
mediated by the p53 coreDNA-binding domain in cooperationwith the
p53 C terminus, whereas the N-terminal domain may have some mod-
ulating effect (26–28). Although apparently unaffected by mutations in
the p53 core domain, p53-DSSB requires an intact tetramerization
domain indicating that the tetramer is the major active form not only in
p53-SSDB (29–31) but also in p53-DSSB (32, 33). In contrast to p53-
SSDB, which is determined by specificity to both sequence and DNA
structure (32, 34), the specific architecture of DNA is the major com-
mon determinant underlying p53 interaction with DNAs that share no
apparent sequence homology. DNA junctions such as those formed in
hairpins, cruciforms, Holliday structures, or recombination intermedi-
ates are important structural elements determining p53 binding (20, 22,
23, 32, 33). Mismatched bases comprise another type of structural ele-
ment to which p53 can bind with varying affinity depending on the type
of mismatch (21). The findings indicate that the specific three-dimen-
sional structure of DNA determines substrate specificity of p53-DSSB.
However, neither the physiological relevance of p53-DSSB nor its sig-
nificance to known p53 activities is fully understood. This is largely due
to the fact that, with the exception of telomeric t-loops (18, 35), no other
naturally occurring genomic sequences are known so far whose recog-
nition by p53would be determined exclusively by the structure of DNA.
The identification of naturally existing genomic sequences with known
functions that can be targeted by p53 via DSSB is of paramount impor-
tance for elucidating whether there is any physiological significance of
p53-DSSB and its relation to p53 functions.
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Considering that p53 binds to unusual DNA structures, wewondered
whether there might be an interaction between p53 and structures
formed by CTGCAG tracts, which represent conformationally flexible
genomic DNA sequences with the propensity to form unusual struc-
tures (36–38). Like many types of repeat sequences, CTGCAG tracts
have a high propensity to be genetically unstable. There ismuch interest
in the mechanisms leading to genetic instability of CTGCAG tracts,
because expansions within them cause a number of different hereditary
neurological diseases, including myotonic dystrophy, Huntington dis-
ease, and several spinocerebellar ataxias (38, 39). Although the molec-
ular details leading to expansion are not completely understood, it has
become clear that the genetic stability of repeat tracts can be influenced
by most aspects of DNA metabolism, including various DNA repair
pathways (38, 39). It is thought that formation of non-linear DNA struc-
tures formed by self-folding of the CTG or the CAG strand is an impor-
tant causative factor of instability associated with CTGCAG repeats
(40–43). Indeed, there is a strong causative relationship between the
formation of hairpin structures by CTGCAG tracts and the occurrence
of DNA breakpoints (reviewed in Ref. 38). Furthermore, expansion of
CAG repeats can activate the DNA damage checkpoint pathway (44),
indicating that cellular factors responsive to DNA damage may be
involved in the control of the CTGCAG DNA stability.
We report in this study that trinucleotide CTGCAG repeats com-
prise a novel physiological p53 target binding site, towhich p53 binds via
p53-DSSB. Our data show for the first time that p53 interacts with
CTGCAG tracts in naked DNA as well as in the context of chromatin
and that p53 binds to alternative conformations adopted by CTGCAG
tracts via different binding modes.Whereas the physiological relevance
of the interaction of p53withCTGCAG tracts remains to be elucidated,
our finding that CTGCAG DNA can be targeted by p53 under physio-
logical conditions is intriguing, because it points to the possibility that
replication-dependent instability of genomic DNA containing
CTGCAG tracts might be influenced by p53.
EXPERIMENTAL PROCEDURES
Preparation of DNA Substrates—DNA-substrates were prepared
from synthetic oligonucleotides shown in TABLE ONE. 100 pmol of
CTG11, CAG11, p53BS-2, or the appropriate sense oligonucleotide were
5-labeled by T4-DNA polynucleotide kinase and [-32P]ATP. To
obtain double-stranded DNA substrates, the 5-labeled sense DNA
strand was annealed with the corresponding unlabeled antisense DNA
strand in 100 l of annealing buffer (10 mM TrisHCl, pH 7.8, 50 mM
KCl, 0.1 mM EDTA) at a molar ratio of 1:2. Structured DNA substrates
were obtained by annealing the 5-labeled CTG11, CAG11, or p53BS-2
DNA with the unlabeled Lock oligonucleotide in 100 l of annealing
buffer at a molar ratio of 1:4. The annealed DNA was purified by elec-
trophoresis in a 8% polyacrylamide gel. Single-stranded labeled oligo-
nucleotides were loaded alongside DNA hybrids as a reference for elec-
trophoretic mobility. The band corresponding to the hybrid DNA
resulting from annealing was excised, submerged into the annealing
buffer, and incubated at 4 °C overnight. Eluted DNA was concentrated
by acetone precipitation and resuspended in the annealing buffer.
Electrophoretic Mobility Shift Assay—DNA binding experiments
were performed using 50 ng of recombinant human p53 proteins
expressed in insect cells and purified as described (32) with or without 1
g of monoclonal antibody in 15 l of DNA binding buffer (10 mM
TrisHCl, pH 7.8, 50 mM KCl, 0.1 mM EDTA, 1 mM dithiothreitol, 20%
(v/v) glycerol) containing 5 ng poly(dI-dC)  poly(dI-dC) and 2 g of
bovine serum albumin. After 20 min of preincubation at room temper-
ature, 20 kcpm of the labeled DNA probe (1–5 ng) in 5 l of DNA
binding buffer were added, and the incubation was continued for
another 20min at room temperature. DNAbinding of SSBwas analyzed
under essentially the same conditions except that the probe was incu-
bated with 25 ng of the SSB protein (Promega, Mannheim, Germany)
either alone or in the presence of p53. The samples were analyzed on a
4% native polyacrylamide gel (10 mM TrisCH3COOH, pH 7.8, 0.1 mM
EDTA, 1.25mMNaOAc, and 10% (v/v) glycerol) and separated at 200 V
for 2 h at room temperature. Gels was dried and subjected to
autoradiography.
DNase I Footprinting—DNA binding by p53 was performed under
the same conditions as described in the previous section. After the bind-
ing step, 30l of DNase I solution (10mMTrisHCl, pH 7.8, 50mMKCl,
8.3 mM CaCl2, 8.3 mM MgCl2, 0.1 mM EDTA, 1 mM dithiothreitol, and
20% (v/v) glycerol) and 0.1 unit of DNase I (Promega) were added, and
the samples were incubated for 10 min at room temperature. The reac-
tion was stopped by adding 50l of stop solution (100mMTrisHCl, pH
8.0, 300 mM NaOAc, 100 mM NaCl, 1% (w/v) SDS, 10 mM EDTA, 200
g/ml proteinase K, 100 g/ml yeast t-RNA). After 15 min of incuba-
tion at 37 °C, the DNA was extracted by phenol-chloroform and recov-
ered by ethanol precipitation. DNA pellets were resuspended in form-
amide loading buffer and analyzed by electrophoresis on a 20%
denaturing polyacrylamide gel.
Cell Culture—LNZ308/2024 clone (kindly provided by Dr. E. G. Van
Meir) is derived from the human glioma cell line LNZ308 and expresses
wild type p53 in the presence of doxycycline (45). The human osteosar-
coma cell line SaOs-2 is null for p53 (ATCC). The cells were cultured in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf
serum at 37 °C in a humidified incubator (5% CO2).
Transient Transfection and Luciferase Reporter Gene Assay—Tran-
sient transfection was performed essentially as described previously
(46). Briefly, LNZ308/2024 cellswere plated into a six-well tissue culture
plate (Nunc, Roskilde, Denmark) at a density 0.2 106/well and trans-
fected by nucleoporation (Amaxa, Ko¨ln, Germany). The transfections
were done in triplicates using 0.5g of reporter DNA/well. Transfected
cells were incubated either in the absence or the presence of doxycycline
(1 g/ml) and harvested 24 h after transfection. Luciferase activity was
measured in lysates prepared from the transfected cells by using the
luciferase assay system from Promega. Luciferase activity was normal-
ized against total protein amounts determined by using the Bio-Rad
protein assay.
Cloning and Stable Transfections—Nineteen CTGCAG19 repeats
were cloned into the AflII site of the pEYFP-C1 vector (Clontech, Hei-
delberg, Germany), which is suitable for transfection of eukaryotic cells
and enables selection of transfected cells by resistance to neomycine.
p53-null SaOs-2 cells were stably transfected with 2.5 g of either
pEYFP-C1 or pEYFP-CTGCAG19 plasmids using EffecteneTM trans-
fection reagent (Qiagen). Transfected cells weremaintained for 3 weeks
in the selection medium containing 0.5 mg/ml G418. Genomic DNA
was isolated from the selected clones resistant to G418 and analyzed for
the presence of pEYFP-C1 or EYFP-CTGCAG19 sequences by PCR
using EYFP-for (5-CATGGTCCTGCTGGAGTTCGTG-3) and
EYFP-rev (5-GGAACAACACTCAACCCTATCTCG-3) primers.
The identities of the resulting PCR products were confirmed by
sequencing. Two of the recombinant clones termed SaOs-2/pEYFP and
SaOs-2/pEYFP-CTGCAG19 were selected for ChIP2 experiments.
ChIP—Wtp53 or mutant R273H proteins were expressed in SaOs-2/
pEYFP or in SaOs-2/pEYFP-CTGCAG19 cells by transient transfection
2 The abbreviations used are: ChIP, chromatin immunoprecipitation; EMSA, electro-
phoretic mobility shift assay; 3WJ, three-way junctions; SSB, single-stranded DNA-
binding protein; ssDNA, single-stranded DNA.
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using p53 expression vectors pCMV-wtp53 (47) or pCMV-Tag-R273H
(kindly provided by S. Dehde), respectively. 2 106 cells were plated in
10-cm dishes and transfected the next day with 2g of pCMV-wtp53 or
pCMV-Tag-R273H using EffecteneTM transfection reagent (Qiagen).
36 h after transfection, ChIP was performed with the polyclonal anti-
body p53(FL-393) (Santa Cruz, Heidelberg, Germany) as described pre-
viously (46). Semi-quantitative PCR was performed in 100 l of PCR
buffer (Eppendorf, Hamburg, Germany) using 100 nM primers, 200 M
dNTPmix, 2 units of TaqDNA polymerase and 10% (v/v) of the immu-
noprecipitated DNA or 1% (v/v) of input DNA. PCR protocol included
an initial denaturation step (2 min at 95 °C) followed by 35 cycles of 50 s
at 95 °C, 50 s at 55 °C, and 1 min at 72 °C. Primers for GAPDH and
mdm2(P2) were those described in Ref. 48. EYFP-for and EYFP-rev
primers were used to amplify stably integrated pEYFP-C1 or pEYFP-
CTGCAG19 (specific PCR products of 520 or 628 bp, respectively).
RESULTS
In Vitro Preparation and Analyses of DNA Structures Formed by
CTGCAGTriplets—Formation of non-canonical DNA structures such
as slipped strand DNA or slipped intermediate DNA are thought to be
the cause of the CTGCAG DNA expansion associated with some neu-
rodegenerative diseases (41, 42, 49). Slipped strand or slipped interme-
diate DNA can result from a misaligned annealing of CTG and CAG
DNA strands that can fold back to form asymmetric hairpin structures
branching out from three-way junctions (3WJ) (36). Therefore, 3WJ
structures that contain hairpin and mismatched duplex formed by self-
annealedCTGorCAGstrands correspond to the basic structural elements
of thebiologically relevantDNAstructures suchas slippedstrandor slipped
intermediate DNA. We prepared DNA templates that recapitulate
CTGCAG tracts either in the canonical B-form (CTGCAGB-duplex), or in
non-canonical DNA conformations (3WJ structures CTGhairpin and
CAGhairpin contain hairpins, whereas CAGCAGAA or CTGCTGTT
DNAs correspond to a mismatched homoduplexes formed by CTG or
CAG repeats, respectively). 3WJ structures were designed as depicted in
supplemental Fig. S1 (shown for CTGhairpin). CTGCTGTT and
CAGCAGAA structures containmultiple pairs of TTorAAmismatches,
respectively. To ensure that the expected structures were formed, we
assessed the DNA structure either enzymatically, using endonucleases
(restriction enzymes or T7-EndoI) or chemically, with OsO4 and diethyl
pyrocarbonate (supplemental Fig. S1). The patterns of the T7-EndoI cleav-
age or reactivity with OsO4 and diethyl pyrocarbonate were fully concord-
ant with the formation of the expected structures and the stereochemical
features established in structural analyses of hairpins formed by CTG or
CAG triplets (50–53).
Interaction of Wild Type p53 with CTGCAG Tracts in Alternative
Conformations of DNA—Having confirmed the structure of our DNA
substrates, we examined p53 binding to different conformations of
CTGCAG tracts by EMSA. Note that 3WJ structures that contain hair-
pins formed by CTG or CAG triplets appear in 4% native polyacryl-
amide gels as two bands migrating with differing mobility (Fig. 1, A,
lanes 9 and 17, and B, lane 17). Whereas the faster migrating band
comprises themajor population of 3WJ structures containing a hairpin,
the form of the DNA contained within the slower migrating band is
unknown. We infer that the slower migrating band corresponds to a
conformational isomer formed by CTG or CAG repeats. Such an inter-
pretation would be concordant with the fact that the slower migrating
band appeared in the preparations of 3WJ structures after they have
been initially isolated as a single band from the preparative 8% gel.
EMSA experiments showed that all of the DNA structures were bound
by wtp53, which formed a single major complex (Fig. 1A, p53DNA
complex in lanes 2, 6, 10, 14, and 18). The complex was specific for p53,
as is evident from the retardation of its mobility in the presence of the
p53-specific antibodyDO-1 (lanes 4, 8, 12, 16, and 20). The specificity of
p53 bindingwas also evident from the characteristic inhibitory effects of
the p53-specific antibody PAb421 (lanes 3, 7, 11, 15, and 19), which
binds at theC-terminal domain of p53 and is a known in vitromodulator
of both p53-SSDB (54) and p53-DSSB (32, 55). The inhibitory effect of
PAb421 on p53 binding has been noted previously with different types
ofDNA templates and is indicative of the involvement of theC-terminal
DNA-binding domain (32–34, 55, 56). The reduced binding in the pres-
ence of PAb421 thus suggests that the C-terminal DNA-binding
domain of p53 is also essential for p53 interaction with the CTGCAG
DNA. Although the pattern of p53 binding to all three DNAs structures
appeared similar, there was a marked quantitative difference in that the
p53 complex formed with 3WJ structures containing a hairpin (lanes
10–12 and 18–20) was significantly more abundant compared with the
complex formed with linear forms of CTGCAG DNA, such as canon-
ical B-duplex (lanes 2–4), or irregular homoduplexes formed byCTGor
CAG strands (lanes 6–8 and 14–16, respectively). Importantly, p53
binding to different isoforms of CTGCAG DNA is specific because
linear p53BS-2lin DNA, which contains p53-binding site from the
mdm2(P2) promoter (57) but lacks CTGCAG repeats, did not bind p53
under the same experimental conditions (Fig. 1A, right panel, compare
lane 8with lanes 2 and 5). Again, PAb421 strongly inhibited p53 binding
to CTGCAG DNA (lanes 3 and 6), whereas p53 binding to p53BS-2lin
was activated (lane 9) as expected (54).
To further corroborate the conclusion that p53 binds preferentially to
CTGCAGDNA in hairpin conformation, we compared the potential of
CTGhairpin or CTGCAGB-duplex DNAs to displace specific DNA from
p53 complexes formed with the canonic (sequence-specific) p53-bind-
ing sites. DNASPEC contains two p53-binding sites, p53BS-1 and
p53BS-2 (TABLE ONE), that comprise full p53 response element from
the mdm2(P2) promoter (57). Whereas p53BS-2 alone does not bind
p53 in the absence of PAb421 (Fig. 1A, substrate p53BS-2lin in the right
panel), DNASPEC binds p53 strongly even in the absence of PAb421
because of the presence of two p53-binding sites, p53BS-1 and p53BS-2
(Fig. 1B, lane 2). The p53 complex with DNASPEC was challenged by
increasing amounts of unlabeled CTGhairpin or CTGCAGB-duplex DNA
(Fig. 1B, lanes 1–10). Whereas DNASPEC was efficiently displaced from
the p53-SSDB complex byCTGhairpin DNAat amolar competitor:probe
ratio of 50 (compare lanes 2 and 8), an at least 4-fold higher ratio was
required to achieve a comparable effect with CTGCAGB-duplex DNA as
competitor (lane 6). Coherent results were obtained in the reciprocal
experiments, in which unlabeled DNASPEC was used as a competitor to
challenge p53 complexes formed with labeled CTGCAGB-duplex (lanes
11–16) or CTGhairpin (lanes 18–22) DNAs. As seen in lane 13,
CTGCAGB-duplex DNAwas efficiently displaced by DNASPEC already at
a molar ratio of 10 (compare with lane 12), whereas an at least 10-fold
higher amount of DNASPEC was required to achieve a similar displace-
ment of CTGhairpin DNA from its complex with p53 (lane 21). Alto-
gether, the results demonstrate that a hairpin represents the preferred
conformation to which p53 binds more efficiently than to a linear form
of CTGCAG DNA.
Wtp53 Binds to Alternative Conformations of CTGCAG Tracts by
Different Binding Modes—To obtain more detailed insight into the
interaction of p53 with CTG tracts, we employed DNase I protection
assay, which allows the identification of protein-binding sites at a single
base resolution. p53 complexes formed with conformationally different
CTGCAG tracts were subjected to limited hydrolysis by DNase I, and
the resulting patterns of DNA protection were compared.
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We first analyzed the interaction of p53 with CTGCAGB-duplex,
which represents a canonical B DNA (Fig. 2A). p53 binding resulted in
the protection of a large area that covered almost the entire length of the
CTG tract in CTGCAGB-duplex DNA (Fig. 2A, lanes 4–8). At the high-
est p53 concentration, a large region comprising 10 CTG triplets (bases
enclosed within the boxed area) became completely protected (lane 8).
Such a pattern is characteristic for non-sequence-specific DNA binding
and indicates that p53 interaction with the CTGCAGB-duplex is unlikely
to be mediated by sequence-specific recognition of individual
CTGCAG triplets.
A different pattern of DNA protection was observed in the CTGhairpin
DNAformedby11CTGtriplets.Bases thatbecameprotectedby thebound
p53 protein were located within two clearly defined regions, each covering
about three CTG triplets. One of the protected regions spanned three trip-
lets proximal to the 5-end, (CTG1-CTG3, numbered from the 5-end
onwards), whereas the other region included triplets CTG9–CTG11 prox-
imal to the 3-end (Fig. 2B, lanes 4–7, triplets enclosed within the boxed
area). Superimposition of the protected baseswith the presumed structure
of CTGhairpin showed that the protected CTG triplets were the ones
engaged in the formationof the stemof thehairpin structure (depictednext
to the gel image in Fig. 2B). The twoprotected regionswere separatedby an
intervening region that remained unprotected (lanes 4–7). Although a
slight protection within the intervening region emerged at the highest
amount of p53 (lane 8), the data clearly demonstrate that the primary p53-
FIGURE 1.Analyses of wtp53 binding to CTGCAG tracts in different conformations by EMSA. A, left panel, DNA structures formed by CTGCAG tracts were incubatedwith 50 ng
of recombinant human wtp53 protein with or without 1 g of purified p53 specific antibodies DO-1 or PAb421. Note that the intensity of bands corresponding to the trimeric
DNAp53DO-1 complexes appears decreased in lanes 4, 8, 12, 16, and 20 compared with lanes 2, 6, 10, 14, and 18, respectively. This is due to the partition of intensity between two
complexes formed in the presence of DO-1 compared with a single complex formed by p53 in the absence of antibody. Right panel, comparison of p53 binding to CTGCAG tracts
(lanes 1–6) and to linear p53BS-2lin DNA, which lacks CTGCAG tracts (lanes 7–9). B, wtp53 binds with different affinities to linear and non-linear conformations of CTGCAG DNA.
Relative affinities of p53 binding were analyzed by reciprocal competition assays. wtp53 (50 ng) was incubated with radioactively labeled DNA probes (indicated below the
corresponding images) in the presence or absence of increasing amounts of unlabeled competitor DNA. The numbers indicate the molar excess of competitor DNA relative to the
amounts of DNA probe (1 ng).
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FIGURE 2. Analyses of wtp53 interaction with CTGCAG DNA by DNase I protection. Images of 20% denaturing polyacrylamide gels showing patterns of wtp53 binding to
different structures formed by CTGCAG tracts (as indicated below gel images). Maxam-Gilbert sequencing ladders corresponding to the labeled strands from each DNA structure
were run alongside to allow theprecise identification of individual bases cleavedbyDNase Iwithin CTGor CAG tracts.A, p53 “footprints” on theCTGCAGB-duplex DNA. Control sample
was treated by DNase I in the absence of p53 (lane 3). Sequence of the labeled strand is shown on the right side of the gel image. Bases enclosedwithin the boxed area are those that
DNA Structure-dependent DNA Binding of p53
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binding site is locatedwithin the stemof thehairpin adjacent to a three-way
junction. Such a pattern is characteristic for site-specific binding and is
reminiscent of the pattern resulting from p53-SSDB, in which a specific
sequence determines the site of p53 binding (supplemental Fig. S2).
Because the region protected by p53 in CTGhairpin DNA lacks any resem-
blance to the p53 consensus (58) and in its base composition is identical to
sequences that remain unprotected, sequence-specific recognition cannot
explain why p53 binds selectively to some but not all CTG triplets within
the CTGhairpin DNA. However, such binding pattern is compatible with a
stereo-specific DNA recognition whereby the structure of DNA deter-
mines the binding site for p53. Thus we conclude that p53 binds to
CTGhairpin in a site-specific binding mode, in which the specificity of the
interaction is determined not by a specific sequence but by the three-di-
mensional configuration of DNA.
We next analyzed the pattern of p53 binding to the CTGCTGTT
DNA, which contains multiple pairs of regularly spaced mismatching
TT bases (Fig. 2C). Surprisingly, the “signature” of p53 bound to
CTGCTGTT was very different from those observed with either
CTGCAGB-duplex or CTGhairpin DNAs. At lower concentrations of p53,
two regions weakly protected by p53 emerged that did not span
throughout the entire CTG tract but localized within CTG triplets
located closer to DNA ends (shown inside the boxed area in Fig. 2C).
Interestingly, the protected regions were separated by two triplets that
initially remained unprotected (indicated by a broken line in Fig. 2C) but
became hypersensitive to DNase I as the concentration of p53 increased
(Fig. 2C, bases indicated by dots). Because the susceptibility to DNase I
strongly depends on structural variations along DNA duplex (59), the
result suggests that binding of p53 might have induced a change in the
structure of CTGCTGTT DNA. To test whether this type of mismatch
matters, we also analyzed the patterns of p53 binding to CAGCAGAA
DNA that contained multiple pairs of AA mismatches. The results
show that, similar to the pattern seen in CTGCTGTT DNA, p53 bind-
ing rendered CAGCAGAA hypersensitive to DNase I within a region
located in the center of the molecule, between the two areas protected
by p53 (Fig. 2D). Importantly, the structural change induced by p53 was
specific to CTGCTGTT and CAGCAGAA DNA, because it did not
occur in CTGCAGB-duplex nor in CTGhairpin DNA (Fig. 2, A and B).
Altogether, the DNase I protection experiments revealed that p53
interacts with CTGCAG tracts by different modes; it binds in a site-
specific mode to the hairpin structure formed by CTG repeats
(CTGhairpin) but not to the canonical B-form of CTGCAG DNA
(CTGCAGB-duplex). In mismatched duplexes formed by CTG or by
CAG strands, p53 binding induces a topological change in DNA exhib-
ited by an increased sensitivity to DNase I.
p53 Promotes Binding of Single-stranded Binding Protein to Irregular
Homoduplexes Containing TT or AA Mismatches—Distortions of the
DNAduplex are often accompanied by local separation ofDNA strands.
We considered the possibility that local disturbances of theDNAduplex
induced by p53 in CTGCTGTT or CAGCAGAA DNAs might lead to
the appearance of regions of single-stranded DNA (ssDNA). To test the
hypothesis, we assessed the ability of single-strandedDNA-binding pro-
tein (SSB) to bind DNA in the absence or the presence of p53. The
rationale behind this experiment was that SSB, which binds preferen-
tially and with high affinity to ssDNA, should be able to “trap” distorted
regions in trinucleotide repeat DNA. In our experiments using limiting
amounts of SSB, fully paired CTGCAGB-duplex DNA did not bind con-
siderably (Fig. 3, lane 16), whereas CTGCTGTT and CAGCAGAA
DNAs bound only weakly to SSB (SSBDNA complex in lanes 4 and 10).
However, upon the addition of p53, SSB binding to CTGCTGTT and
CAGCAGAA DNAs increased dramatically in a p53 dose-dependent
manner (lanes 5, 6, 11, and 12, respectively). In contrast, SSB binding to
CTGCAGB-duplex was influenced only modestly by p53 (lanes 17 and
18). The results support the idea that the enhanced formation of
SSBDNA complexes is due to a change in DNA structure induced by
p53. In accordance with such an explanation, the effects of p53 were
considerably more pronounced with CTGCTGTT and CAGCAGAA
became protected at the highest amounts of p53 (lane 8). B, p53 binds to a well defined site in the CTGhairpin DNA. Sequence of the labeled strand is shown as plain (along the gel
image) or in hairpin conformation corresponding to its actual arrangement in the CTGhairpin DNA (most right image). C, and D, patterns of p53 binding to irregular duplexes
CTGCTGTT andCAGCAGAA homoduplexes containingmultiple TT or AAmismatches, respectively. Ts or As engaged in the formationofmismatches are shownas protruding in the
corresponding sequences next to the gel images. Broken lines mark the areas that became hypersensitive to DNase I in the presence of p53. Individual bases that became
hypersensitive are marked by dots.
FIGURE 3. Wtp53 stimulates DNA binding of
SSB. Effects of p53 on DNA binding of SSB ana-
lyzed by EMSA. DNA was incubated in the pres-
ence of p53, SSB, or both proteins. The amount of
SSB was kept constant (25 ng), whereas wtp53
amounts varied (as indicated).
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homoduplexes (lanes 1–12), which are highly prone to topological dis-
tortions, than with the more stable CTGCAGB-duplex DNA (lanes
13–18). That p53 did not induce larger SSBDNA complexes as would
be expected if more SSB homotetramers would bind cooperatively to
the sameDNAmolecule is also concordantwith a scenario inwhich p53
facilitates SSB binding by increasing the population of DNA molecules
containing ssDNA regions. Notably, SSB-specific complexes, which can
be easily distinguished from the slower migrating p53 complex,
migratedwith the samemobility either in the absence or presence of p53
(compare lanes 4 and 10with lanes 5 and 6 and lanes 11 and 12, respec-
tively). The finding that either SSBDNA complexes or p53DNA com-
plexes are seen in EMSA but no ternary complexes (containing DNA,
p53, and SSB) indicates that p53, while promoting SSB binding to
ssDNA, can be displaced by SSB from DNA. Such a mechanism has
been described for the dynamic interaction between p53 and other
DNA structure-dependent proteins such as HMGI(Y), which displaces
p53 from Holliday junctions (24). Stimulation of SSB binding to
CTGCTGTT or CAGCAGAA DNAs by p53 without formation of a
ternary complex is reminiscent of the interaction between p53 and the
mismatch repair protein complex hMSH2/6, which enhances p53 bind-
ing to Holliday junctions or to bulged DNAwithout direct participation
in the p53DNA complex (24).
p53 Proteins Bind Specifically to CTGCAG Tracts in the Context of
Chromatin—To further test the idea that CTGCAG tracts represent
novel type of p53-binding sites, we next analyzed p53 interaction with
CTGCAG DNA in vivo. To address the question we established stable
clones carrying stretches of 19 uninterrupted CTGCAG repeats inte-
grated into the chromatin of SaOs-2 cells (clone SaOs-2/EYFP-
CTGCAG19). Clones carrying EYFP vector DNA lacking transgenic
CTGCAG repeats (clone SaOs-2/EYFP) were analyzed in parallel as a
negative control. p53 binding to genomic DNAwas assessed by ChIP in
cells that were transiently transfected with an expression vector encod-
ing wtp53 (Fig. 4). Expression of p53 was ascertained by Western blot
analysis of lysates prepared from the transfected cells (Fig. 4B).GAPDH-
DNA, to which p53 does not bind was included as a negative control in
our PCR analyses of the recovered genomic DNA (upper panel in Fig.
4A). As expected, wtp53 bound specifically to themdm2(P2) promoter
in cells containing both SaOs-2/EYFP and in SaOs-2/EYFP-
CTGCAG19 (Fig. 4A,middle panel, lanes 4 and 10, respectively). Hav-
ing ascertained that our experimental conditions allow detection of spe-
cific p53-DNA interactions, we tested whether p53 binds to CTGCAG
DNA in the context of chromatin. The results show thatwtp53 bound to
the CTGCAG19 tract in SaOs-2/EYFP-CTGCAG19 cells, as evidenced
by PCR using the EYFP-for and EYFP-rev primers that flank the
CTGCAG19 insert (lower panel, lane 10). Confirming the specificity of
binding, no PCR product was obtained with the same primers in the
control reactions with genomic DNA from SaOs-2/EYFP cells, which
lack the transgenic CTGCAG19 sequence (Fig. 4A, lower panel, lane 4).
The results of ChIP analyses thus demonstrate that wtp53 binds specif-
ically to CTGCAG tracts in vivo.
An important question was whether upon integration into the
genome of SaOs-2 cells the model CTGCAG19 repeats had retained a
linear or assumed a non-linear conformation. Because this question is
difficult to analyze by direct means, we took advantage of our previous
finding that binding to linear DNA is completely lost by mutant p53
proteins (33, 60). Supplemental Fig. S3A shows that this also true in the
case of linear CTGCAG DNA, which does not bind the R273H p53
mutant, as evidenced by DNase I protection experiments. In contrast,
R273Hmutant did bind to CTGhairpin and CTGCTGTT DNAs, and the
resulting patterns of DNA protection were similar to those seen with
wtp53 (supplemental Fig. S3, B and C). Analyses of DNA binding by
ChIP revealed that R273H bound to the transgenic CTGCAG19 repeats
in the context of chromatin and with the efficacy comparable with that
of wtp53 (Fig. 4A, lower panel, lane 12). Considering that mutant p53
proteins are deficient for binding to linear DNA, these results indicate
that transgenic CTGCAG19 repeats most likely adopt a non-B DNA
FIGURE 4. Wtp53 and R273H mutant bind to
CTGCAG tracts in the chromatin context. A,
ChIP analyses of genomic DNA bound by p53 in
chromatin. ChIP experiments were performed
with SaOs-2 cells that contained stably integrated
a model CTGCAG tract (clone SaOs-2/EYFP-
CTGCAG19) or an “empty” pEYFP-C1 vector (clone
SaOs-2/EYFP). The cells were transiently trans-
fectedwithMock DNA (pUC18) or with expression
plasmids that encode wtp53 or R273H. Input DNA
was subjected to PCRwith each primer used (sam-
ples in lanes IN). GenomicDNAwas recovered from
immunoprecipitates obtained either with anti-
p53 antibody () or without antibody (). Control
PCRs were set with PCR primers specific for
GAPDH-DNA (negative control) or mdm2(P2) pro-
moter DNA (positive control) (shown in the upper
and middle panels, respectively). B, comparable
levels of wtp53 and of R273H expression in SaOs-
2/EYFP-CTGCAG19 or SaOs-2/EYFP cells was con-
firmed by Western blot analysis using anti-p53
antibody DO1.
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conformation in the context of chromatin. As expected, R273Hmutant
did neither bind to the endogenousmdm2(P2) promoter (middle panel,
lanes 6 and 12) nor to the GAPDH-DNA (upper panel, lanes 6 and 12),
indicating that R273H binds to the integrated CTGCAG19 repeat DNA
specifically. Notably, DNase I protection experiments showed that not
only was R273H potent for binding to mismatched homoduplexes in
vitro, it also, similarly to wtp53, induced local hypersensitivity to DNase
I in the CTGCTGTT DNA (supplemental Fig. S3C, lane 12). However,
the potential of R273H to bind to CTGCTGTT DNA and to induce
structural changes in DNAduplex was considerably weaker than that of
wtp53 (compare lanes 7–12 with lanes 1–6, respectively). Thus p53
mutant R273H, which is impaired for binding to the canonic B-form of
DNA, retains the potential to bind non-canonic structures formed by
CTG repeats such as hairpin or mismatched duplex.
DISCUSSION
In this study,wedemonstrate thatCTGCAGrepetitive sequences com-
prise a novel type of specific p53-binding site, to which p53 binds in vitro
and in vivo. Interaction between p53 and CTGCAG tracts is determined
not by a specific sequence but by the structure of DNA, thereby identifying
CTGCAG tracts as a binding target in p53-DSSB. Our in vitro analyses
reveal that p53 can interact with different conformations of CTGCAG
tractsbydistinctmodes. In thecanonicalB-form,CTGCAGrepeatDNAis
bound by p53 in a non-sequence-specific manner. However, upon forma-
tion of a hairpin conformation within the CTGCAG tracts, structural fea-
tures are created in the DNA that promote p53 binding in a site-specific
manner. The identification of CTGCAG tracts as a novel type of p53-
specific target site provides the first evidence that the specific interaction of
p53 with DNA is not restricted to p53-SSDB but may be mediated also by
p53-DSSB under physiological conditions. An important implication from
these findings is that the pool of p53-specific binding sites might be much
larger than estimated from searches that were based exclusively on the
analysis of p53 consensus sequences (61–63).
Identification of CTGCAG tracts as a novel p53 target DNA raises
the question of a physiological significance of such interaction. Consid-
ering that specific DNA binding is a prerequisite for transcriptional
activationmediated by p53, one obvious possibility to considerwould be
that CTGCAG tracts may act as non-canonical p53 response elements.
We have examined such a possibility by the reporter assay using a chi-
meric promoter derived from themdm2(P2) promoter, from which the
intrinsic (sequence-specific) p53 response element was deleted and
replaced by 92 CTGCAG repeats in either orientation (Fig. 5,
mdm2(CAG)-LUC and mdm2(CTG)-LUC). The results showed that
the CTGCAG92 tract did not render either of the chimeric promoters
responsive to wtp53 (Fig. 5), indicating that p53 interaction with
CTGCAG tracts may be not relevant for regulation of transcription.
However, more studies are required to ascertain the potential of
CTGCAG tracts to act as p53 response elements unambiguously.
Another possibility is that p53 interaction with CTGCAG tracts (or
possibly more general, p53-DSSB) may be important in processes other
than regulation of transcription. In this regard, p53 activities associated
with DNA repair should be considered. Our finding that p53 interacts
with different conformational isoforms of CTGCAG tracts in various
modes reveals striking parallels with findings made for the mismatch
repair protein hMSH2, which also binds to CTGCAG tracts in a DNA
structure-dependent mode (64). Similarly to our findings with p53,
hMSH2 binds to CTGCAG tracts specifically and with wide ranging
affinity, depending on the type of structure, with slipped strand DNA
and linear DNA being the most and the least preferred conformations,
respectively (64). Furthermore, there is a direct mechanistic link
between p53-DSSB andmismatch repair processes as revealed by earlier
studies demonstrating that hMSH2 stimulates p53 binding to Holliday
junctions in vitro (24) and co-localizes with p53 at discrete chromatin
loci in living cells (65). In conjunction with the fact that CTGCAG
tracts represent a common binding target for both hMSH2 (64) and for
p53 (this study) and that DNA is thought to be the connecting compo-
nent in the complex and interdependent interplay between p53 and
hMSH2 activities (24), it is tempting to speculate that the activities of
p53 in DNA repair may be relevant for its interaction with CTGCAG
tracts. In this regard, it is important that instability associated with
CTGCAG tracts arises during normal DNAmetabolic processes, such
as replication and/or transcription (38). Considering that p53 binds to
FIGURE 5. Assessment of the potential of
CTGCAGtracts to functionasp53 responseele-
ments by the reporter assay. Mdm2-LUC plas-
mid (74) contains a luciferase gene under the
control of the mdm2(P2) promoter (57), which
contains two p53-binding sites (p53BS-1 and
p53BS-2). Mdm2p53BS-LUC contains a deriva-
tive of the mdm2(P2) promoter, from which
both p53BS-1 and p53BS-2 sites have been
deleted. The derivatives of mdm2p53BS-LUC,
mdm2(CTG)-LUC, and mdm2(CAG)-LUC contain
92 (CTGCAG92) repeats in sense or antisense ori-
entation, respectively, cloned instead of BS-1
and BS-2. Luciferase activity (counts normalized
to the total protein amounts) reflects activities
of the mdm2(P2) promoter and its derivatives in
the absence (black bars) or the presence (gray
bars) of p53.DOX, doxycycline.
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CTGCAG tracts in cells in the absence of DNAdamage (this study), the
possibility that maintenance of CTGCAG tract stability may be one of
the-stand by-functions of non-activated p53 must be considered (see
the Introduction). Such an interpretation would be in accordance with
the general idea that maintenance of genomic integrity may be one of
the functions of “latent” p53 (8, 66). Considering that there is a causative
relationship between human diseases and different types of DNA triplet
repeats including CTGCAG triplets (41), an obvious direction for
future investigations would be to test whether p53 may interact with
different types of DNA triplet repeats that are relevant for human
pathologies known as triplet repeat diseases. A connection between p53
activity and triplet repeat diseases has been revealed in a recent study
demonstrating that p53 single nucleotide polymorphism at codon 72
may be involved in the modulation of the age of onset of Huntington
disease patients (67). Furthermore, there is also evidence for a direct
mechanistic link between p53 and Huntington disease at the level of
protein interaction; p53 and Huntington disease proteins interact with
each other, and intriguingly, expansion of CAG triplets from the hun-
tingtin gene impairs binding of mutant htt protein to p53 (68).
Our finding that p53 induces local distortions in mismatched
CTGCTGTT and CAGCAGAA duplexes suggests that p53 may be
involved in the maintenance of the CTGCAG tracts stability. One pos-
sible scenario is that non-canonical DNA structures that contain TT or
AAmismatchesmay be targeted by p53, which then binds to and desta-
bilizes such DNA structures. Such scenario would be concordant with
the notion that p53, by binding to DNA, can affect DNA topology as
demonstrated previously. p53 can influence DNA topology by different
means, of which bending, twisting, or denaturation are some that occur
on double-stranded DNA (69), whereas the re-annealing activity of p53
prevails with ssDNA (70, 71). Our observation that p53 stimulates
ssDNA binding of SSB suggests that destabilization of unusual and
potentially recombinogenic structures formed by CTGCAG tractsmay
involve the concerted action of p53 and single-stranded DNA-binding
proteins, which can resolve secondary structures from ssDNA (72, 73).
In such a scenario, the co-operative action of p53 and ssDNA-binding
proteins may provide an efficient mechanism to prevent formation of
potentially “dangerous” DNA structures in unstressed cells, even when
the amounts of non-activated p53 are limited.
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